Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
Conditions
Von Hippel-Lindau Disease · Carcinoma, Renal Cell
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Karmanos Cancer Center ( Site 0108), Detroit, Michigan, United States
START San Antonio ( Site 0104), San Antonio, Texas, United States
UZ Leuven ( Site 0900), Leuven, Vlaams-Brabant, Belgium
Rambam Health Care Campus ( Site 1600), Haifa, Israel
Hadassah Medical Center ( Site 1604), Jerusalem, Israel
Sourasky Medical Center ( Site 1603), Tel Aviv, Israel
N.N. Blokhin NMRCO ( Site 2101), Moscow, Moscow, Russia
Russian Scientific Center of Radiology and Surgical Technologies ( Site 2100), Saint Petersburg, Sankt-Peterburg, Russia
Samsung Medical Center ( Site 2902), Gangnam, Seoul, South Korea
Severance Hospital, Yonsei University Health System ( Site 2901), Seodaemun-gu, Seoul, South Korea
Asan Medical Center ( Site 2900), Seoul, South Korea
Hospital Universitario 12 de Octubre ( Site 2301), Madrid, Spain
Taipei Veterans General Hospital ( Site 2800), Taipei, Taiwan
ME І.І. Mechnykov Dnipro Regional Clinical Hospital ( Site 2601), Dnipropetrovsk, Dnipropetrovsk Oblast, Ukraine
CNCE Precarpathian Clinical Oncologic Center ( Site 2600), Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine
Study leads
Medical Director
Study Director
Merck Sharp & Dohme LLC